Domov › Atopični dermatitis (ekcem) › Pennsylvania
Klinične študije za Atopični dermatitis (ekcem) v Pennsylvania
13 študij za Atopični dermatitis (ekcem) išče udeležence na lokacijah v Pennsylvania.
Mesta v Pennsylvania
Uradno besedilo študije (angleško)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- UPMC - Department of Dermatology- Site Number : 8400024, Pittsburgh
Vključevanje udeležencevOpazovalna študija
Starost 12 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Camp Hill
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07298395A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Paddington Testing Co, Inc, Philadelphia
- UPMC Department of Dermatology, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18–64 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07216027A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07003425A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Best Skin Research LLC, Camp Hill
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07223697A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Best Skin Research, LLC, Camp Hill
- UPMC Department of Dermatology, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18–65 · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07599813FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Paddington Testing Company, Philadelphia
Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci
Starost 18–70 · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT06564389A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Research of Philadelphia /ID# 264972, Philadelphia
- University of Pittsburgh Medical Center /ID# 264526, Pittsburgh
- Dermatology Associates of Plymouth Meeting /ID# 267286, Plymouth Meeting
Vključevanje udeležencevFaza 3
Starost 18–63 · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT06389136The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
- University of Pittsburgh Medical Center, Pittsburgh
- UPMC Department of Dermatology, Pittsburgh
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 4. maj 2026 · NCT06928246A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Paddington Testing Co, Inc, Philadelphia
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 4. maj 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8559, Philadelphia
- Galderma Investigational Site 7103, Philadelphia
Vključevanje udeležencevOpazovalna študija
Starost 12 in več · Vsi spoli · Posodobljeno 13. mar. 2026 · NCT06988605Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- University of Pittsburgh Medical Center, Pittsburgh
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 30. dec. 2025 · NCT00177268A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- DermDox Centers for Dermatology, Camp Hill
- University of Pennsylvania, Philadelphia
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 19. sep. 2025 · NCT06055361Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.